Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery

BioArctic, a Swedish biotechnology company renowned for its innovative approach

Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Novo Holdings has led a $100 million Series C financing

Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion

Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion

Eli Lilly and Company, a global leader in pharmaceutical development,

Why UCB Is Betting $1.15 Billion That Cell Therapy Can Change Epilepsy

Why UCB Is Betting $1.15 Billion That Cell Therapy Can Change Epilepsy

Biotech’s IPO Window Is Reopening—But Only for Companies Wall Street Can Underwrite

Biotech’s IPO Window Is Reopening—But Only for Companies Wall Street Can Underwrite

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Why UCB Is Betting $1.15 Billion That Cell Therapy Can Change Epilepsy
Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease
Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda
Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top